These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 15004512

  • 1. 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
    Chauhan D, Li G, Auclair D, Hideshima T, Podar K, Mitsiades N, Mitsiades C, Chen LB, Munshi N, Saxena S, Anderson KC.
    Apoptosis; 2004 Mar; 9(2):149-55. PubMed ID: 15004512
    [Abstract] [Full Text] [Related]

  • 2. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
    Yang M, Huang J, Pan HZ, Jin J.
    Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856
    [Abstract] [Full Text] [Related]

  • 3. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
    Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC.
    Oncogene; 2004 Nov 18; 23(54):8766-76. PubMed ID: 15480425
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P, Galán-Malo P, Marzo I, Naval J.
    Leuk Res; 2012 Feb 18; 36(2):212-8. PubMed ID: 21978467
    [Abstract] [Full Text] [Related]

  • 5. Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.
    Chauhan D, Li G, Hideshima T, Podar K, Shringarpure R, Mitsiades C, Munshi N, Yew PR, Anderson KC.
    Oncogene; 2004 Apr 29; 23(20):3597-602. PubMed ID: 15094775
    [Abstract] [Full Text] [Related]

  • 6. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 7. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.
    Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, Podar K, Mitsiades N, Mitsiades C, Li C, Kim RS, Munshi N, Chen LB, Wong W, Anderson KC.
    Blood; 2003 May 01; 101(9):3606-14. PubMed ID: 12480690
    [Abstract] [Full Text] [Related]

  • 8. Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
    Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC.
    Cancer Res; 2003 Oct 01; 63(19):6174-7. PubMed ID: 14559800
    [Abstract] [Full Text] [Related]

  • 9. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B, Anderson KC.
    Cancer Res; 2005 Sep 15; 65(18):8350-8. PubMed ID: 16166312
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ.
    Clin Cancer Res; 2007 Nov 01; 13(21):6469-78. PubMed ID: 17975159
    [Abstract] [Full Text] [Related]

  • 11. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 12. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
    Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC.
    Br J Haematol; 2006 Jul 01; 134(2):145-56. PubMed ID: 16846475
    [Abstract] [Full Text] [Related]

  • 13. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T, Ozaki K, Mori M, Nagai T, Muroi K, Kano Y, Furukawa Y, Ozawa K.
    Oncogene; 2009 Jan 15; 28(2):231-42. PubMed ID: 18850009
    [Abstract] [Full Text] [Related]

  • 14. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H, Hideshima T.
    Tanpakushitsu Kakusan Koso; 2006 Aug 15; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract] [Full Text] [Related]

  • 15. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells.
    Koizumi M, Nakaseko C, Ohwada C, Takeuchi M, Ozawa S, Shimizu N, Cho R, Nishimura M, Saito Y.
    Eur J Haematol; 2007 Nov 15; 79(5):382-91. PubMed ID: 17903213
    [Abstract] [Full Text] [Related]

  • 16. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
    Balsas P, López-Royuela N, Galán-Malo P, Anel A, Marzo I, Naval J.
    Biochem Pharmacol; 2009 Mar 01; 77(5):804-12. PubMed ID: 19100720
    [Abstract] [Full Text] [Related]

  • 17. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
    Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C.
    J Cell Biochem; 2008 Jan 01; 103(1):270-83. PubMed ID: 17516511
    [Abstract] [Full Text] [Related]

  • 18. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
    Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N, Anderson KC.
    Br J Haematol; 2007 Feb 01; 136(3):414-23. PubMed ID: 17173546
    [Abstract] [Full Text] [Related]

  • 19. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
    Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC.
    Cancer Cell; 2005 Nov 01; 8(5):407-19. PubMed ID: 16286248
    [Abstract] [Full Text] [Related]

  • 20. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
    Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades N.
    Invest Ophthalmol Vis Sci; 2007 Oct 01; 48(10):4706-19. PubMed ID: 17898295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.